Navigation Links
ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
Date:4/1/2008

="http://www.istavision.com" target="_new">http://www.istavision.com.

Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. Without limiting the foregoing, but by way of example, statements contained in this press release related to the completion of the data analysis and discussions with the FDA regarding the Xibrom QD NDA or possible new Xibrom products and the possibility of a label change for the currently marketed 0.09% formulation of Xibrom, bringing a new product to market every 12 to 18 months, and becoming the leading niche ophthalmic pharmaceutical company are forward- looking statements. Except as required by law, ISTA disclaims any intent or obligation to update any forward-looking statements. These forward-looking statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others: timely and successful implementation of ISTA's strategic initiatives; delays and uncertainties related to ISTA's research and development programs (including the difficulty of predicting the timing or outcome of product development efforts and the FDA or other regulatory agency approval or actions); uncertainties and risks regarding market acceptance of and demand for ISTA's approved products and the impact of competitive products and pricing; uncertainties and risks related to ISTA's ability to properly manage its growth; uncertainties and risks regarding the continued timely performance by ISTA's strategic partners of their respective obligations under existing collaborations and licensing arrangements; uncertainties and risks related to the continued availability of third party sourced products and raw materials on commercially reasonable terms, or at all; uncertai
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
2. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
3. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
4. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
5. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
6. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
7. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
8. VIA Pharmaceuticals Completes Enrollment In Phase 2 Carotid Endarterectomy (CEA) Trial
9. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
10. BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
11. Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... -- Hospira, Inc. (NYSE: HSP ), ... spoke about the importance of extrapolation in bringing biosimilars ... annual European Biosimilars Group conference in London ... publication of a pivotal white paper titled, "Why ... biosimilars." Speaking at the EGA conference, ...
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ABBV ... Administration (FDA) has accepted its New Drug Application (NDA) ... two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), ... of adults with chronic genotype 4 (GT4) hepatitis C ... first all-oral, interferon-free therapy being evaluated by the FDA ...
(Date:4/23/2015)... 23, 2015 Once again, BeaconMedaes is meeting ... to patient safety. BeaconMedaes, priority is to ... disease. The next generation Zone Valve Box ... are now mounted in the assembly, allowing for ease ... ceiling tiles potentially releasing dust spores and other bacteria ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2
(Date:4/27/2015)... The Radiology Business Management Association ... applied business information and intelligence, is proud to announce ... newsletter for its more than 2,000 members. , “RBMA ... news sources in that it is exclusively devoted to ... radiology. The newsletter is produced in cooperation with Thorn ...
(Date:4/27/2015)... Doping has been around sports for years ... continue to capture the public’s imagination, but so-called smart ... performance enhancement along with new ethical considerations. In an ... Anjan Chatterjee of Pennsylvania Hospital and the ... of these enhancements in sports. , Chatterjee studies the ...
(Date:4/27/2015)... 2015 Jvion, the Atlanta-based leader in ... and recognized as one of the top 40 fastest ... is presented by the Atlanta Business Chronicle, honors Atlanta’s ... status as an economic capital and employment hub. , ... spurred by the growing need to improve healthcare quality ...
(Date:4/26/2015)... Indianapolis, Indiana (PRWEB) April 26, 2015 ... network service provider announces that Brotherhood Mutual Insurance Company ... Daniel Armstrong, Manager of Network Infrastructure at Brotherhood Mutual ... value and the service reliability Brotherhood Mutual needed. ... route diversity, and IFN worked with us to ensure ...
(Date:4/26/2015)... This annual celebration is one of the ... include a spectacular collection of vendors offering distinctive gifts ... incense, chimes, vases, candleholders, fleece throws, trivets, jewelry and ... collection of vendors, guests will have the opportunity to ... Jimmie Jazz Band. , “We are ecstatic to ...
Breaking Medicine News(10 mins):Health News:Radiology Business Management Association Launches Weekly Legislative and Policy Newsletter 2Health News:The Brain, Smart Drugs, and Sports on SCI TV with Anjan Chatterjee 2Health News:The Brain, Smart Drugs, and Sports on SCI TV with Anjan Chatterjee 3Health News:Jvion Named to Top 40 Atlanta 2015 Pacesetters 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 3Health News:It’s Coming! The 5th Annual Tulip Festival & Mother’s Day Celebration at Honor's Haven Resort & Spa! 2
... Pays Cash When You Are Sick or Hurt?COLUMBUS, Ga., March 2 ... Aflac Duck as the mystery benefactor to policyholders who ... humorously shows how Aflac pays cash benefits when a medical ... night in a dark parlor. A group of friends is comforting ...
... March 2 DATATRAK International, Inc. (Nasdaq: ... global eClinical solutions for the clinical trials industry, today ... of Research and Development. In his role as DATATRAK,s ... to Raymond J. Merk, DATATRAK,s Chief Financial Officer and ...
... LCA-Vision Inc. (Nasdaq: LCAV ), a ... Plus (R) brand, today announced that members of its executive ... Institutional Investors Conference on Monday, March 9, 2009 at 8:40 ... The JW Marriott Grande Lakes Hotel in Orlando, Fla. ...
... study of children ages 8-11 years shows contact ... Athletic Competence, and Social Acceptance , JACKSONVILLE, ... benefits to children beyond simply correcting their nearsightedness ... physical appearance, acceptance among friends, and ability to ...
... Workplace Awards, Ten Honored for Best PracticesWASHINGTON, March ... can be felt across all industries, workplaces that ... times reap rewards for employer and employees alike, ... Psychologically Healthy Workplace Awards ceremony yesterday. Five organizations ...
... its 15,000th wish this summer , ... Pickering, ON, (PRWEB) March 2, ... three and 17 are diagnosed with a life-threatening illness. Every day more ... the efforts of The Children,s Wish Foundation of Canada and ...
Cached Medicine News:Health News:New Aflac Commercial Asks, 'Who Dun It?' 2Health News:New Aflac Commercial Asks, 'Who Dun It?' 3Health News:DATATRAK International, Inc. Announces the Return of Chris Wilke as Vice-President of R&D and the Issuance of a Patent 2Health News:DATATRAK International, Inc. Announces the Return of Chris Wilke as Vice-President of R&D and the Issuance of a Patent 3Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 2Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 3Health News:Children's Self-Perceptions Improve More With Contact Lenses vs. Glasses 4Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 2Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 3Health News:Top Employers Find That in Tough Economic Times, a Healthy, Productive Workplace is More Important Than Ever 4Health News:Children's Wish, Canada's National Wish Granting Foundation Celebrates 25 Years 2Health News:Children's Wish, Canada's National Wish Granting Foundation Celebrates 25 Years 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: